title: Cost-Effective but Bad for Health? Hepatitis C Treatment, Moral Hazard, and Opportunity Cost.
authors.affiliation: Division of Clinical Decision Making, Department of Medicine, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies and Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts.
authors.forename: John B
authors.initials: JB
authors.lastname: Wong
authors.affiliation: Division of Clinical Decision Making, Department of Medicine, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies and Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts.
authors.forename: Joshua T
authors.initials: JT
authors.lastname: Cohen
mesh_terms: D000998:Antiviral Agents; D003362:Cost-Benefit Analysis; D005838:Genotype; D016174:Hepacivirus; D006526:Hepatitis C; D006801:Humans; D009014:Morals
chemical_list: D000998:Antiviral Agents